Combination Therapy Development for Breast Cancer

Breast cancer remains one of the most prevalent cancers globally, accounting for a significant proportion of cancer-related deaths among women. At Alfa Cytology, our dedicated team of biologists and oncology experts has been at the forefront of exploring innovative combination therapies to address this critical healthcare concern.

Introduction of Combination Therapy for Breast Cancer

Traditional monotherapies often fall short due to issues like drug resistance, toxicity, and insufficient effectiveness, particularly in advanced or metastatic cases. Consequently, combination therapies—utilizing two or more therapeutic agents targeting different pathways—have emerged as a promising strategy to enhance treatment outcomes.

Fig.1 Schematic illustration of current treatments for breast cancer. (Wang Y., et al. 2022)

Combination therapies can significantly improve survival rates by addressing the multifaceted nature of breast cancer. For instance, combining molecular-targeted therapies with endocrine treatments has shown enhanced efficacy in hormone receptor-positive subtypes, where resistance to single-agent therapies is common. Additionally, immunotherapy has gained traction, particularly for TNBC, which lacks effective targeted treatments.

Combination Therapy Development for Breast Cancer

Ongoing clinical trials of novel combination therapies for breast cancer are paving the way for more effective treatment options. By targeting multiple pathways and utilizing diverse therapeutic modalities, these trials hold the potential to improve outcomes.

NCT	Category	Therapeutics	Phase
NCT02764541	Cyclin-dependent Kinase Inhibitors + Endocrine Therapy	Letrozole + Tamoxifen + Palbociclib + Endocrine Therapy
NCT03113825	E-cadherin/ROS1 Inhibitor	Crizotinib + Fulvestrant
NCT04551495	Tyrosine Kinase Inhibitor + Hormone Therapy	Tyrosine Kinase Inhibitor + Letrozole + Goserelin
NCT05041101	Anti-inflammatory Drug + Microtubule Inhibitor	Grapiprant and Eribulin
NCT03202316	PD-L1 Antibody + Kinase Inhibitors + Microtubule Inhibitor	Atezolizumab + Cobimetinib + Eribulin
NCT01036087	Anti-EGFR Antibody + Mitotic Inhibitor + Cytostatics	Panitumumab + Nab-paclitaxel + Carboplatin

Our Services

At Alfa Cytology, we specialize in the development and optimization of combination therapies for breast cancer. Our comprehensive range of services includes:

Combination Immunochemotherapy
Synergistic Ferroptosis-starvation Therapy
Combination of Photodynamic Therapy (PDT) with Immunotherapy
Combination of Sonodynamic Therapy (SDT) with Chemotherapy

Combination of Radiotherapy with Targeted Therapy
Combination Chemo-photodynamic Therapy
Combination of Chemodynamic Therapy (CDT) with Photothermal Therapy (PTT)
And More

For inquiries about our services or to discuss potential collaborations in combination therapy development for breast cancer, please contact us at Alfa Cytology. Our dedicated team of experts is eager to assist in advancing your research objectives and contributing to the fight against breast cancer.

Reference

Wang Y., Minden A. Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. Int J Mol Sci. 2022, 23(19): 11046.

All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.